(IN BRIEF) GSK has announced that the European Medicines Agency (EMA) has accepted its regulatory application for a prefilled syringe presentation of Shingrix, its recombinant zoster vaccine (RZV) for preventing shingles. This new presentation simplifies administration for healthcare providers by … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, United Kingdom
Tagged adult immunisation, adult vaccination, EMA, European Medicines Agency, European Union, FDA, GSK, healthcare professionals, herpes zoster, herpes zoster prevention, liquid adjuvant, lyophilised antigen, post-herpetic neuralgia, post-herpetic neuralgia prevention, Prefilled Syringe, Recombinant Zoster Vaccine, reconstitution, regulatory application, RZV, Shingles, Shingrix, submission, U.S. FDA, vaccination, vaccine
(IN BRIEF) GSK and the University of Oxford have launched the GSK-Oxford Cancer Immuno-Prevention Programme, a new research initiative focused on cancer prevention through vaccination. GSK is investing up to £50 million to explore how precancerous cells develop into cancer, … Read the full press release
Posted in Education, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Cancer Prevention, cancer vaccines, clinical trials, early-stage cancer, GSK, GSK-Oxford Cancer Immuno-Prevention Programme, GSK’s immune system expertise, immune system, immuno-oncology, Institute of Molecular and Computational Medicine, neoantigen sequencing, neoantigens, Peter Kyle, precancer biology, Professor Irene Tracey, targeted therapies, Tony Wood, translational research, tumor-specific proteins, University of Oxford, vaccination, vaccinology
(IN BRIEF) Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approved gene therapy for Duchenne muscular dystrophy (DMD). The results showed statistically significant and clinically meaningful improvements … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology
Tagged 10-meter walk/run, 10MWR, clinical data, clinical efficacy, crossover group, delandistrogene moxeparvovec, disease-modifying treatment, Duchenne muscular dystrophy, Elevidys, EMBARK trial, external control group, functional improvements, gene therapy, micro-dystrophin, motor function, muscle biopsies, muscle function preservation, muscle pathology, North Star Ambulatory Assessment, NSAA, Phase III study, regulatory approvals, Roche, safety profile, Sarepta Therapeutics, Time to Rise, TTR
(IN BRIEF) Fresenius has signed a five-year global contract with Microsoft to enhance IT collaboration and security for its global workforce. Beginning in June 2025, the agreement will include tools such as Microsoft Defender, Microsoft 365, SharePoint, OneDrive, and Microsoft … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Science, Security & Safety, Technology
Tagged AI enablement, Chief Information Officer, cloud computing, cloud migration, collaboration, data protection, Digital Ecosystem, Fresenius, global contract, Helios Group, Ingo Elfering, IT framework, IT security, Michael Sahnau, Microsoft, Microsoft 365, Microsoft Defender, Microsoft Germany, Microsoft Power BI, OneDrive, partnership, SECURITY, SharePoint
(IN BRIEF) Evotec, Yonsei University, and Zymedi have been awarded a US$ 4.5 million grant from the Korea Institute of Advanced Technology (KIAT) to develop first-in-class biologic therapies for lung diseases, specifically asthma and idiopathic pulmonary fibrosis (IPF). The project … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Germany, Government, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology
Tagged anti-fibrotic antibodies, anti-inflammatory antibodies, antibody development, asthma, biologic therapies, disease-causing enzymes, Evotec, fibrosis, idiopathic pulmonary fibrosis, IPF, KIAT, Korea Institute of Advanced Technology, lung diseases, novel mechanism-of-action, novel therapies, partnership, preclinical R&D, Sunghoon Kim, therapeutic antibodies, Thomas Hanke, tRNA synthetases, unmet medical needs, US$ 4.5 million grant, Yonsei University, Zymedi
(IN BRIEF) Dr. Melissa Webby of the University of Warwick has received a £2.2 million Wellcome Career Development Award to research the mechanisms that protect Gram-negative bacteria from antibiotics. This award supports Dr. Webby’s mission to advance the understanding of … Read the full press release
Posted in Awards, Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged antibiotic resistance, antimicrobial resistance, Awards, bacterial envelope, biomedical research, Colin Kleanthous, Dr. Melissa Webby, Gram-negative bacteria, healthcare infections, leadership, microbiology, public health, research fellowship, University of Warwick, Wellcome Career Development Award
(IN BRIEF) Sanofi’s Sarclisa has been approved by the European Union as the first anti-CD38 therapy in combination with VRd to treat adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. This approval is … Read the full press release
Posted in Business, European Union, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged CD38 monoclonal antibody, clinical development, clinical trials, European Union approval, FDA approval, hematologic malignancies, immunoscience, isatuximab, Multiple Myeloma, NDMM, oncology, orphan drug exclusivity, Sanofi, Sarclisa, transplant-ineligible, treatment breakthrough, VRd
(IN BRIEF) Researchers from the University of Copenhagen and Rigshospitalet have made significant strides in developing a new treatment for pancreatic cancer using antibody-drug conjugates (ADCs). This targeted therapy promises to improve survival rates by precisely attacking cancer cells while … Read the full press release
Posted in Business, Denmark, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged ADC, antibody-drug conjugates, cancer treatment, chemotherapy, colon cancer, Finsen Laboratory, human clinical trials, immune system, Lars Henning Engelholm, pancreatic cancer, pharmaceutical research, precision medicine, Rigshospitalet, sarcoma, Science Advances, survival rates, targeted therapy, triple-negative breast cancer, University of Copenhagen
(IN BRIEF) HealthSage AI has launched its open platform featuring three clinical applications aimed at streamlining physician workflows. These applications, powered by an optimized Large Language Model, improve administrative tasks, billing accuracy, and data exchange. In collaboration with Amsterdam UMC … Read the full press release
Posted in Artificial Intelligence (AI), Business, Financial, Healthcare, Industrial, Investment, Management, Netherlands, News, Technology
Tagged administrative burden, AI healthcare applications, AI platform, AI-Driven Solutions, Amsterdam UMC Heart Center, clinical data transformer, clinical research, data-driven healthcare, FHIR, generative AI, healthcare AI, Healthcare Innovation, healthcare workflow, HealthSage AI, ICD-10, Large Language Model, medical coding, medical data standards, open platform, partnership, patient care, SNOMED-CT, value-based healthcare, visit preparation
(IN BRIEF) New research published in the European Heart Journal has shown that intermuscular fat, which accumulates between muscles, significantly increases the risk of heart disease, heart attack, and heart failure, regardless of body mass index (BMI). Led by Professor … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged body mass index, Brigham and Women's Hospital, cardiac risk assessment, Cardiovascular risk, chest pain, CMD, coronary microvascular dysfunction, Dr. Ranil de Silva, European Heart Journal, exercise, fatty muscle fraction, heart attack, heart disease, heart failure, Imperial College London, insulin resistance, intermuscular fat, lean muscle, metabolic syndrome, muscle fat, Nutrition, Obesity, PET/CT scanning, Professor Viviany Taqueti, shortness of breath, subcutaneous fat, treatment strategies, weight-loss therapies, WOMEN
(IN BRIEF) The University of Exeter has developed a new algorithm for interpreting blood test results, helping GPs detect potential cancer warning signs earlier, particularly through variations in platelet count. The Royal Devon University Healthcare NHS Foundation Trust is the … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged algorithm, Australia, blood test, bowel cancer, CANADA, Cancer Detection, Cancers journal, David Walton, Devon, early diagnosis, early warning signs, England, Exeter HealthTech Research Centre, general practitioners, GP, High or Elevated Level of Platelets (HELP) Flag, lung cancer, medical research, National Institute for Health and Care Research, NHS, patient outcomes, personalized thresholds, platelet count, platelet variation, Professor Sarah Bailey, RDUH, Royal Devon University Healthcare NHS Foundation Trust, University of Exeter
(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation. The approval is based on … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged acalabrutinib, AstraZeneca, autologous hematopoietic stem cell transplantation, bendamustine, blood cancers, Bruton’s tyrosine kinase, BTK inhibitor, Calquence, chemoimmunotherapy, COVID-19, Dave Fredrickson, ECHO Phase III trial, FDA, global regulatory review, international markets, Lymphoma Research Foundation, mantle cell lymphoma, MCL, Meghan Gutierrez, Michael Wang, oncology, PFS, progression-free survival, Project Orbis, regulatory submission, rituximab, safety profile, U.S. approval
(IN BRIEF) A new study from the University of Bristol has challenged the long-standing belief that waking up triggers a spike in cortisol, the body’s stress hormone. Published in Proceedings of the Royal Society B, the research shows that cortisol … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged automated sampling system, BBSRC, Biotechnology and Biological Sciences Research Council, CAR, chronic fatigue syndrome, circadian rhythm, cortisol, cortisol awakening response, cortisol dynamics, cortisol secretion, depression, Dr. Thomas Upton, EU Horizon 2020, medical school, Proceedings of the Royal Society B, Professor Marcus Munafò, Professor Stafford Lightman, PTSD, research findings, Sleep, sleep disorders, stress hormone, Ultradian grant, University of Bristol
(IN BRIEF) GRAHAM Building North is partnering with Glasgow Children’s Hospital Charity to raise funds, with a team of 20 employees participating in a charity skydive this August. Nearly £4,000 has been raised toward their £20,000 target, which will fund … Read the full press release
Posted in Business, Construction, Financial, Government, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, News, United Kingdom
Tagged 000, 000 donation, 000 target, 10, 20 %, 300 raised, bake sale, charity skydive, Chris MacLeod, Christmas Jumper Day, Easter decorations, employee involvement, festive event, fundraising, Glasgow Children’s Hospital Charity, GRAHAM Building North, Head of Partnerships, inter-divisional football tournament, mobile sensory units, Northern Ireland, partnership, philanthropy, Regional Director, Santa’s Grotto, Scotland’s largest children’s hospital, silver plate victory, support services, tombola, William McGowan, young patients, £1, £4
(IN BRIEF) AstraZeneca and Daiichi Sankyo’s Biologics License Application (BLA) for datopotamab deruxtecan has been accepted by the U.S. FDA for treating advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in patients who have previously received systemic therapies. The … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged advanced NSCLC, antibody-drug conjugate, AstraZeneca, Biologics License Application, BLA, breakthrough therapy designation, Daiichi Sankyo, datopotamab deruxtecan, drug approval, EGFR-mutated, EGFR-tyrosine kinase inhibitors, FDA, metastatic NSCLC, non-small cell lung cancer, NSCLC, objective response rate, oncology, partnership, Phase III Trials, Priority Review, safety profile, systemic therapies, TROP2-directed, TROPION-Lung01, TROPION-Lung05, TROPION-Lung14, TROPION-Lung15
(IN BRIEF) Savills has appointed Joel Gazeres to its Operational Capital Markets (OCM) division, where he will focus on growing the Healthcare and Senior Living team. Gazeres joins from CBRE, bringing 20 years of expertise in healthcare real estate, including … Read the full press release
Posted in Business, Healthcare, Industrial, Management, News, Real Estate, United Kingdom
Tagged appointment, care homes, Caryn Donahue, CBRE, Consultancy, debt financing, development, director, equity financing, Europe, Healthcare and Senior Living, healthcare real estate, healthcare sector, Joel Gazeres, leadership, net lease transactions, OCM, Operational Capital Markets, RESEARCH, Savills, Savills Healthcare and Senior Living team, sector knowledge, Senior Housing Transactions, specialist care, strategic consultancy, supported living, transactional consultancy, transactional experience, UK, valuation
(IN BRIEF) Sarclisa, an anti-CD38 treatment developed by Sanofi, has been approved in China for treating adult patients with relapsed or refractory multiple myeloma (R/R MM) who have received at least one prior therapy. The approval is based on the … Read the full press release
Posted in Business, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology
Tagged anti-CD38 antibody, autologous stem cell transplant, bortezomib, CACA, Category I Recommendation, Chinese Anti-Cancer Association, Chinese Society of Clinical Oncology, clinical data, CSCO, dexamethasone, Global Head of Oncology, ICARIA-MM phase 3 study, innovative regulatory pathways, innovative therapies, IsaFiRsT real-world study, Lecheng Pilot Program, lenalidomide, local authorities, medical community, National Medical Products Administration, newly diagnosed multiple myeloma, NMPA, Olivier Nataf, overall response rate, overall survival, Pd, pomalidomide, R/R MM, real-world evidence, regulatory submission, relapsed or refractory multiple myeloma, RWE, Sanofi, Sanofi in China, Sarclisa
(IN BRIEF) A prototype of the Liverpool Diagnostic Infrared Wand (LDIR Wand), developed by the University of Liverpool in collaboration with the Liverpool Head and Neck Cancer Centre, has shown promising results in diagnosing oral cancer. The device uses a … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged cancer diagnosis, cancer prognosis, Cancer Research UK, clinical application, commercialization, early cancer detection, funding, haematoxylin and eosin staining, i4i programme, infrared spectral images, LDIR Wand, Liverpool Diagnostic Infrared Wand, Liverpool Head and Neck Cancer Centre, machine learning algorithm, National Institute for Health and Care Research, oral cancer, Professor Peter Weightman, Professor Richard Shaw, technological innovation, tissue analysis, University of Liverpool, “prototype”
(IN BRIEF) TÜV Rheinland has introduced a new Eye Comfort Certification for laptops at CES 2025, a groundbreaking 5-star rating system designed to assess laptop screens for visual comfort. This certification evaluates key factors like image quality, ambient light control, … Read the full press release
Posted in Awards, Business, Environment, Financial, Germany, Healthcare, Industrial, Investment, Management, Media, News, Security & Safety, Technology
Tagged 5-star rating, ambient light control, Asus, Awards, certification database, Certipedia, CES 2025, consumer decision-making, Dell, display technology, eye care technologies, Eye Comfort Certification, HP, image quality, Intelligent CCT Control, Intelligent Luminance Control, Jay Yang, Laptops, leadership, Lenovo, multimedia designers, safety, screen comfort, TÜV Rheinland, TÜV Rheinland Greater China Electrical, visual comfort
(IN BRIEF) GSK has announced that the FDA has accepted its application to review a prefilled syringe version of Shingrix, its shingles vaccine. This new version, expected to be available from January 2025, eliminates the need for reconstitution, offering a … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged administration, adults 50 and over, antigen, AS01B adjuvant system, chickenpox, FDA, glycoprotein E, GSK, healthcare community, healthcare professionals, immune response, immunodeficiency, immunosuppression, liquid adjuvant, lyophilised, non-live vaccine, Prefilled Syringe, recombinant subunit vaccine, Recombinant Zoster Vaccine, reconstitution, RZV, safety, Shingles, shingles prevention, shingles vaccine, Shingrix, Shingrix approval, vaccine composition, Vaccine Innovation, vaccine presentation, vaccine safety, varicella, varicella-zoster virus
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?